Changes to This Summary (10/25/2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Revised text to state that increasing data are available on the outcomes of interventions to reduce risk in people with a genetic susceptibility to breast cancer or ovarian cancer.
Added text to state that evidence strongly supports the integral role of breast magnetic resonance imaging in breast cancer surveillance for BRCA1/2 mutation carriers.
Added text about a population-based case-control study that found no increased risk of contralateral breast cancer among BRCA1/2 carriers exposed to radiation for primary breast cancer compared to carriers not exposed to radiation (cited Bernstein et al. as reference 502).
Added text about how the molecular mechanisms that explain the improved prognosis in hereditary BRCA-associated ovarian cancer may be related to the function of BRCA genes. (cited Yang et al. and Xu et al. as references 528 and 529, respectively).
Added text about two genetic registry–based studies that explored the risk of primary breast cancer after BRCA-related ovarian cancer; these studies suggest that oophorectomy and platinum-based chemotherapy for the treatment of ovarian cancer may confer protection against subsequent breast cancer (cited Domchek et al. and Vencken et al. as references 537 and 538, respectively).
This summary is written and maintained by the PDQ Cancer Genetics Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.